|Articles|October 1, 2003
Blocking Agent
New York - A recent in vitro study uncovered specific details of the immunoregulatory agent, fontolizumab (HuZAFTM), showing the biologic modifier as able to block transcripts induced by the naturally occurring human protein, interferon-gamma, said Jules Cohen, M.D., at the International Psoriasis Symposium.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results
2
KT-621 Produces 98% STAT6 Degradation in AD Patients
3
DeepSeek-R1 Outperforms ChatGPT-4o in Urticaria Clinical Queries
4
Abeona Initiates First Commercial Treatment of Zevaskyn for RDEB
5















